A Phase I/II Study of CP-4055 in Patients With Refractory/Relapsed Hematologic Malignancies

NCT00405743 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

153

Enrollment

INDUSTRY

Sponsor class

Conditions

Hematologic Malignancies
AML

Interventions

DRUG: CP-4055
DRUG: CP-4055

Sponsor

Clavis Pharma